Patents by Inventor Barbara Mui

Barbara Mui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LIPID NANOPARTICLE mRNA VACCINES
    Publication number: 20260090989
    Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
    Type: Application
    Filed: December 5, 2025
    Publication date: April 2, 2026
    Applicants: CureVac SE, Acuitas Therapeutics Inc.
    Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHMIDT, Ying TAM
  • Lipid nanoparticle formulations
    Patent number: 12491261
    Abstract: Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: December 9, 2025
    Assignee: Acuitas Therapeutics, Inc.
    Inventors: Michael J. Hope, Barbara Mui, Paulo Jia Ching Lin, Christopher J. Barbosa, Thomas D. Madden, Steven M. Ansell, Xinyao Du
  • LIPID NANOPARTICLE mRNA VACCINES
    Publication number: 20250288522
    Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
    Type: Application
    Filed: May 27, 2025
    Publication date: September 18, 2025
    Applicants: CureVac SE, Acuitas Therapeutics Inc.
    Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHMIDT, Ying TAM
  • LIPID NANOPARTICLE FORMULATIONS
    Publication number: 20230372537
    Abstract: Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 23, 2023
    Inventors: Michael J. Hope, Barbara Mui, Paulo Jia Ching Lin, Christopher J. Barbosa, Thomas D. Madden, Steven M. Ansell, Xinyao Du
  • Lipid nanoparticle formulations
    Patent number: 11712481
    Abstract: Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: August 1, 2023
    Assignee: Acuitas Therapeutics, Inc.
    Inventors: Michael J. Hope, Barbara Mui, Paulo Jia Ching Lin, Christopher J. Barbosa, Thomas D. Madden, Steven M. Ansell, Xinyao Du
  • SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
    Publication number: 20220074925
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: April 2, 2021
    Publication date: March 10, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • LIPID NANOPARTICLE MRNA VACCINES
    Publication number: 20210251898
    Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
    Type: Application
    Filed: January 6, 2021
    Publication date: August 19, 2021
    Applicants: CureVac AG, Acuitas Therapeutics Inc.
    Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHMIDT, Ying TAM
  • SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
    Publication number: 20200225215
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: June 14, 2019
    Publication date: July 16, 2020
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • LIPID NANOPARTICLE MRNA VACCINES
    Publication number: 20200163878
    Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
    Type: Application
    Filed: October 26, 2017
    Publication date: May 28, 2020
    Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT, Ying TAM
  • LIPID NANOPARTICLE FORMULATIONS
    Publication number: 20200121809
    Abstract: Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 23, 2020
    Inventors: Michael J. Hope, Barbara Mui, Jia Ching Paulo Lin, Christopher J. Barbosa, Thomas D. Madden, Steven M. Ansell, Xinyao Du
  • SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
    Publication number: 20180209963
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: September 1, 2017
    Publication date: July 26, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • DELIVERY OF TARGET SPECIFIC NUCLEASES
    Publication number: 20180185516
    Abstract: Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.
    Type: Application
    Filed: December 8, 2017
    Publication date: July 5, 2018
    Inventors: Steven M. Ansell, Christopher Barbosa, Anthony Conway, Xinyao Du, Michael J. Hope, Michael C. Holmes, Gary K. Lee, Paulo Jia Ching Lin, Thomas Madden, Barbara Mui
  • SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
    Publication number: 20160274089
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: October 30, 2015
    Publication date: September 22, 2016
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS
    Publication number: 20140295449
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: October 21, 2013
    Publication date: October 2, 2014
    Applicant: Tekmira Pharmaceuticals, Inc.
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Home, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS
    Publication number: 20120225434
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: May 1, 2012
    Publication date: September 6, 2012
    Applicants: ALNYLAM PHARMACEUTICALS, INC., The University of British Columbia, Tekmira Pharmaceuticals Corporation
    Inventors: Marco A. CIUFOLINI, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS
    Publication number: 20110117125
    Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    Type: Application
    Filed: December 31, 2008
    Publication date: May 19, 2011
    Applicants: TEKMIRA PHARMACEUTICALS CORPORATION, THE UNIVERSITY OF BRITISH COLUMBIA, ALNYLAM PHARMACEUTICALS
    Inventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Barbara Mui, Pieter R. Cullis, Marco A. Ciufolini, Kim F. Wong, Muthiah Manoharan, Rajeev G. Kallanthottathil
  • SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS
    Publication number: 20110097720
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: December 31, 2008
    Publication date: April 28, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, De Fougerolles Antonin, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Compositions and methods for stabilizing liposomal drug formulations
    Publication number: 20090285878
    Abstract: The present invention is directed to liposomal compositions comprising a camptothecin, which are optimized to reduce camptothecin degradation and/or precipitation of camptothecin degradation products in the external medium. The invention further provides improved methods of formulating liposomal camptothecins, kits comprising liposome-encapsulated camptothecins, and methods of using the same to treat a variety of diseases and disorders, including cancer.
    Type: Application
    Filed: November 4, 2005
    Publication date: November 19, 2009
    Applicant: Tekmira Pharmaceuticals Corporation
    Inventors: Michael J. Hope, Barbara Mui, Thomas D. Madden
  • Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
    Publication number: 20060008909
    Abstract: The present invention includes novel liposomes comprising dihydrosphingomyelin. The invention also includes compositions comprising these liposomes and a therapeutic agent, in addition to methods and kits for delivering a therapeutic agent or treating a disease, e.g., a cancer, using these compositions.
    Type: Application
    Filed: May 16, 2005
    Publication date: January 12, 2006
    Applicant: Inex Pharmaceuticals Corporation
    Inventors: Pieter Cullis, Thomas Madden, Michael Hope, Steven Ansell, Barbara Mui, Sean Semple, Norbert Maurer
  • Compositions for stimulating cytokine secretion and inducing an immune response
    Publication number: 20050249794
    Abstract: Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of a antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid which is included in the lipid-nucleic acid particle can be a phosphodiester (i.e.
    Type: Application
    Filed: February 26, 2004
    Publication date: November 10, 2005
    Inventors: Sean Semple, Troy Harasym, Sandra Klimuk, Ljiljiana Kojic, Jonathan Bramson, Barbara Mui, Michael Hope